Stockreport

Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel

Bellicum Pharmaceuticals, Inc.  (BLCM) 
Last bellicum pharmaceuticals, inc. earnings: 3/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.bellicum.com/investor-overview
PDF SAN DIEGO, Dec. 02, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for canc [Read more]